JP2014221729A - Elastin production promoter - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an elastin production promoter which is broadly applicable to external preparation for skins and the like, such as pharmaceutical preparations, quasi drugs, and cosmetic preparations, because of being capable of promoting an elastin production effectively and being expected to prevent and improve aging processes, such as wrinkle, dullness, and decreased elasticity of skin which advance with age.SOLUTION: Provided is an elastin production promoter containing as an active ingredient at least one kind selected from carnitine and salts thereof and carnitine derivatives and salts thereof.

Description

  The present invention relates to an elastin production promoter. More specifically, the present invention relates to an elastin production promoter that contains carnitine or the like and can be used as a skin external preparation such as cosmetics.

  The skin consists of the stratum corneum, epidermis, basement membrane and dermis from the outside. The dermis is filled with a network of macromolecules called the extracellular matrix. This extracellular matrix is produced in fibroblasts in the dermis and the like, and is composed of polysaccharides called acidic mucopolysaccharides such as hyaluronic acid and dermatan sulfate, and fibrous proteins such as collagen and elastin. Extracellular matrix is directly involved in skin elasticity, agitation, freshness, metabolism, etc. When the production of extracellular matrix in fibroblasts is dull, the elasticity and freshness of skin are lost, Wrinkles, wrinkles and rough skin are more likely to occur, contributing to skin aging.

  Fibrous proteins are composed of collagen and elastic fibers, and are closely related to skin wrinkles. For example, collagen provides tension to the skin, while elastic fibers provide elasticity that restores the skin temporarily deformed by pressurization. The elastic fiber having such a function has a fibrillar structure (micro-fibril) having no striated pattern and an amorphous structure filling the gap, and is composed of fibrillin and elastin, respectively. Of these, elastin accounts for about 2% of the total protein in the dermis, making a stretchable network structure like rubber. Thus, the elasticity of the skin is highly dependent on elastin in elastic fibers existing in the dermis layer. For this reason, the decrease or alteration of elastin in the skin is a factor that impairs the flexibility and elasticity of the skin, and causes skin aging such as wrinkles, sagging and a decrease in skin elasticity. In addition, it is known that elastin production of fibroblasts decreases with aging.

Accordingly, there is an increasing demand for elastin production promoters and the like that increase elastin in order to suppress skin aging and improve skin elasticity.
Currently, elastin production promoters that have been reported include glycogen (Patent Document 1) and plant extracts (Patent Document 2), but their effects are not sufficient, and more powerful elastin production promoters are required. ing.

JP 2012-062273 A JP 2012-056933 A

An object of the present invention is to provide an excellent elastin production promoter in view of the above situation.

As a result of repeated studies on elastin production promoters, the present inventors have found that carnitine, carnitine derivatives and the like have excellent elastin production promoting ability, and have completed the present invention. That is, the present invention includes the following items [1] to [9].
[1] An elastin production promoter comprising as an active ingredient at least one selected from carnitine and salts thereof and carnitine derivatives and salts thereof.
[2] The above-mentioned [1], wherein the carnitine and a salt thereof and a carnitine derivative and a salt thereof are a compound represented by the following general formula (1) and a compound represented by the general formula (2): The elastin production promoter as described.

（式中、Ｒ⁰は炭素数１〜３７の脂肪族炭化水素基、水素原子、−ＣＯＲ¹のいずれかを表す。Ｒ¹は炭素数１〜３６の脂肪族炭化水素基を示す）

(In the formula, R ⁰ represents any of an aliphatic hydrocarbon group having 1 to 37 carbon atoms, a hydrogen atom, and —COR ^1. R ¹ represents an aliphatic hydrocarbon group having 1 to 36 carbon atoms)

（式中、Ｒ⁰は前記式（１）と同様であり、Ｘ^-はｍ価の無機アニオンまたは有機アニオンを表し、Ｙ⁺はｎ価の無機カチオンまたは有機カチオンを表す。ｍおよびｎはそれぞれ独立に１〜４の整数を表す）

(In the formula, R ⁰ is the same as in the above formula (1), X ⁻ represents an m-valent inorganic anion or organic anion, and Y ⁺ represents an n-valent inorganic cation or organic cation. Independently represents an integer of 1 to 4)

[3] The compound represented by the general formula (1) is a compound represented by the following general formula (3), and the compound represented by the general formula (2) is a compound represented by the following general formula (4). The elastin production promoter according to [2] above.

（式中、Ｒ¹は炭素数１〜３６の脂肪族炭化水素基を表す）

(Wherein R ¹ represents an aliphatic hydrocarbon group having 1 to 36 carbon atoms)

（式中、Ｒ¹は前記式（３）と同様であり、Ｘ^-およびＹ⁺は前記一般式（２）と同様である）

(In the formula, R ¹ is the same as in the above formula (3), and X ⁻ and Y ⁺ are the same as in the general formula (2)).

[4] The compound represented by the general formula (3) is a compound represented by the following general formula (5), and the compound represented by the general formula (4) is a compound represented by the following general formula (6). The elastin production promoter according to [3] above.

（式中、Ｒ²およびＲ³はそれぞれ独立に、炭素数１〜１８の脂肪族炭化水素基を表す）

(In the formula, R ² and R ³ each independently represents an aliphatic hydrocarbon group having 1 to 18 carbon atoms)

（式中、Ｒ²およびＲ³は一般式（５）と同様であり、Ｘ^-およびＹ⁺は前記一般式（２）と同様である）

(Wherein R ² and R ³ are the same as in general formula (5), and X ⁻ and Y ⁺ are the same as in general formula (2)).

[5] In the above [4], R ² and R ^{3 in the} formulas (5) and (6) are each independently an aliphatic hydrocarbon group having ³ to 16 carbon atoms. Elastin production promoter.
[6] In each of the above formulas (5) and (6), any one of R ² and R ³ is an n-hexyl group, and the other is an n-octyl group, [4] ] The elastin production promoter as described in above.
[7] X ⁻ in the above formulas (2), (4) and (6) is a hydroxide ion, nitrate ion, sulfate ion, carbonate ion, bicarbonate ion, halide ion, formate ion, acetate ion, Selected from the group consisting of citrate ions, tartrate ions, oxalate ions, fumarate ions, anions of fatty acids having 3 to 20 carbon atoms, anions of carnitine and its derivatives, anions of ascorbic acid, anions of ascorbyl phosphate and its derivatives The elastin production promoter according to any one of [2] to [6] above, wherein the elastin production promoter is an anion.

[8] Y ⁺ in the above formulas (2), (4) and (6) is derived from cations of hydrogen ion, sodium ion, potassium ion, calcium ion, magnesium ion, zinc ion, ammonium ion, carnitine and derivatives thereof. The elastin production promoter according to any one of [2] to [7] above, which is selected from the group consisting of:
[9] Any of [1] to [8] above, wherein the content of at least one selected from carnitine and a salt thereof and a derivative of carnitine and a salt thereof is 0.2 to 500 mM. The elastin production promoter according to claim 1.

  The elastin production promoter of the present invention can effectively promote the production of elastin, and can be expected to prevent and improve aging phenomena such as wrinkles of skin, wrinkles, decreased elasticity, etc. that progress with aging. It can be widely applied to skin external preparations such as quasi drugs and cosmetics.

Hereinafter, the present invention will be specifically described.
The elastin production promoter of the present invention contains, as an active ingredient, at least one selected from carnitine and salts thereof and carnitine derivatives and salts thereof. That is, the elastin production promoter of the present invention may contain any one of carnitine, a carnitine derivative, a carnitine salt, and a carnitine derivative salt, or two or more of these. It may be. Further, two or more kinds of carnitine derivatives, two or more kinds of carnitine salts, and two or more kinds of carnitine derivatives may be contained.
<Carnitine and its derivatives>
Carnitine and carnitine derivatives used for the elastin production promoter of the present invention are not particularly limited, and may be synthesized or extracted from nature.
Carnitine is a compound having the following structure.

カルニチンの誘導体としては限定されないが、例えばカルニチンの炭素原子に結合した水素原子がアルキル基、水酸基、ニトロ基、アミノ基、スルホニル基等の置換基で置換されたもの、水酸基の水素原子が脂肪族炭化水素基等で置換されたものなどが挙げられる。中でも、水酸基の水素原子が脂肪族炭化水素基等で置換された誘導体が好ましい。

The derivative of carnitine is not limited. For example, a hydrogen atom bonded to a carbon atom of carnitine is substituted with a substituent such as an alkyl group, a hydroxyl group, a nitro group, an amino group, or a sulfonyl group, and the hydrogen atom of the hydroxyl group is aliphatic. Examples thereof include those substituted with a hydrocarbon group. Of these, derivatives in which the hydrogen atom of the hydroxyl group is substituted with an aliphatic hydrocarbon group or the like are preferable.

  Carnitine and carnitine derivatives are preferably represented by the structure of the following general formula (1).

式（１）中、Ｒ⁰は炭素数１〜３７の脂肪族炭化水素基、水素原子、−ＣＯＲ¹のいずれかを表す。Ｒ¹は炭素数１〜３６の脂肪族炭化水素基を示す。Ｒ⁰が表す脂肪族炭化水素基およびＲ¹は、分岐を有していてもいなくてもよく、飽和でも不飽和でもよい。中でもＲ⁰は、水素または−ＣＯＲ¹であることが好ましい。

In the formula (1), R ⁰ represents any one of an aliphatic hydrocarbon group having 1 to 37 carbon atoms, a hydrogen atom, and —COR ¹ . R ¹ represents an aliphatic hydrocarbon group having 1 to 36 carbon atoms. The aliphatic hydrocarbon group represented by R ⁰ and R ¹ may or may not have a branch, and may be saturated or unsaturated. Of these, R ⁰ is preferably hydrogen or —COR ¹ .

When R ⁰ is an aliphatic hydrocarbon group, the carbon number is preferably 1 to 25, and more preferably 5 to 18. When R ⁰ is an aliphatic hydrocarbon group, it is preferably a saturated aliphatic hydrocarbon group, more preferably an alkylene group. The alkylene group may be branched or linear. R ⁰ preferably has no substituent, but may have a substituent as long as the physical properties of the compound are not affected.

When R ¹ is an aliphatic hydrocarbon group, the characteristics are the same as those of the aliphatic hydrocarbon group described in R ⁰ .
The general formula (1) is more preferably represented by the following general formula (3).

式（３）中、Ｒ¹は式（１）におけるものと同様である。
上記一般式（３）は、さらに好ましくは下記一般式（５）で示される。

In formula (3), R ¹ is the same as that in formula (1).
The general formula (3) is more preferably represented by the following general formula (5).

式（５）中、Ｒ²およびＲ³はそれぞれ独立に炭素数１〜１８の脂肪族炭化水素基を表す。Ｒ²およびＲ³は、分岐を有していてもいなくてもよく、飽和でも不飽和でもよい。前記Ｒ²およびＲ³は、いずれか一方が炭素数１〜１６ の脂肪族炭化水素基であり、他方が炭素数３〜１６の脂肪族炭化水素基であることが好ましい。さらに、前記Ｒ²およびＲ³は、それぞれ独立に炭素数３〜１６の脂肪族炭化水素基であることがより好ましく、それぞれ独立に炭素数４〜１２の脂肪族炭化水素基であることがさらに好ましい。

In formula (5), R ² and R ³ each independently represents an aliphatic hydrocarbon group having 1 to 18 carbon atoms. R ² and R ³ may or may not have a branch, and may be saturated or unsaturated. One of R ² and R ³ is preferably an aliphatic hydrocarbon group having 1 to 16 carbon atoms, and the other is an aliphatic hydrocarbon group having 3 to 16 carbon atoms. Furthermore, R ² and R ³ are more preferably each independently an aliphatic hydrocarbon group having 3 to 16 carbon atoms, and each independently being an aliphatic hydrocarbon group having 4 to 12 carbon atoms. preferable.

In addition, the carnitine site | part of a carnitine derivative is a L type normally. Moreover, carnitine derivative represented by the general formula (5), since it has a α- branched acyl group having R ² and R ^3, the branch point in the case where R ² and R ³ are different from each other The α carbon atom of a becomes an asymmetric carbon atom, and an optical isomer exists. In the carnitine derivative of the present invention, the optical isomer based on the α carbon atom is not particularly limited, and any of them may be a mixture of these optical isomers.

Since the carnitine derivative represented by the general formula (5) has an α-branched acyl group having R ² and R ³ , electrons in the ester bond site by the branched chain are present even in the presence of an aqueous medium. It is considered that the acyl group is hardly hydrolyzed due to the donating reduction effect and can exist stably over a long period of time.

Specifically, R ² and R ³ are, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, n-hexyl group, 2-methylpentyl group, 3-methylpentyl group, 4-methylpentyl group, 2-ethylbutyl group, n-heptyl group, 2-methylhexyl group, 3-methylhexyl group, 4-methylhexyl Group, 2-ethylpentyl group, 3-ethylpentyl group, n-octyl group, 2-methylheptyl group, 3-methylheptyl group, 4-methylheptyl group, 5-methylheptyl group, 6-methylheptyl group, 2 -Ethylhexyl group, 3-ethylhexyl group, 4-ethylhexyl group, 2-propylpentyl group, n-nonyl group, n-decyl group, n-undecyl group, n-dodecyl group, - tridecyl, n- tetradecyl, n- pentadecyl, n- hexadecyl group, heptadecyl group into n-, n- octadecyl group, include straight-chain or branched alkyl groups such as isostearyl group.

Specific examples of R ² and R ³ include 10-undecenyl group, 9-hexadecenyl group, cis-9-octadecenyl group, 11-octadecenyl group, cis, cis-9,12-octadecadienyl group, Examples thereof include linear or branched alkenyl groups such as 9,12,15-octadecatrienyl group, 6,9,12-octadecatrienyl group, and 9,11,13-octadecatrienyl group.

Among these, the combination of preferred R ² and R ^3, and R ² and R ³ is methyl group and a methyl group, a methyl group and an ethyl group, a methyl group and n- propyl group, a methyl group and an isopropyl group,
Methyl group and n-butyl group, methyl group and n-pentyl group, methyl group and n-hexyl group, methyl group and n-octyl group, methyl group and n-decyl group, methyl group and n-tetradecyl group, methyl group And n-hexadecyl group, ethyl group and ethyl group, ethyl group and n-propyl group, ethyl group and isopropyl group, ethyl group and n-butyl group, ethyl group and isopropyl group, ethyl group and n
-Butyl group, ethyl group and n-pentyl group, ethyl group and n-hexyl group, ethyl group and n-octyl group, ethyl group and n-decyl group, ethyl group and n-tetradecyl group, ethyl group and n-hexadecyl Group, n-propyl group and n-propyl group, n-propyl group and n-butyl group, n-propyl group and n-pentyl group, n-propyl group and n-hexyl group, n-butyl group and n-hexyl group And a combination of an n-butyl group and an n-octyl group, an n-hexyl group and an n-octyl group. Of these, a combination of an n-hexyl group and an n-octyl group is most preferable.
In the saccharification reaction inhibitor of the present invention, the carnitine derivative specified by the combination of R ² and R ³ may be used singly or in combination of two or more.

<Salts of carnitine and its derivatives>
The elastin production promoter of the present invention may contain at least one of a carnitine salt and a salt of the carnitine derivative. Specifically, the salt is a compound represented by the following formula (2), more preferably a compound represented by the formula (4), and further preferably a compound represented by the formula (6).

（式中、Ｒ⁰は前記式（１）と同様であり、Ｘ^-はｍ価の無機アニオンまたは有機アニオンを表し、Ｙ⁺はｎ価の無機カチオンまたは有機カチオンを表す。ｍおよびｎはそれぞれ独立に、１〜４の整数である）

(In the formula, R ⁰ is the same as in the above formula (1), X ⁻ represents an m-valent inorganic anion or organic anion, and Y ⁺ represents an n-valent inorganic cation or organic cation. Independently, an integer from 1 to 4)

（式中、Ｒ¹は前記式（３）と同様であり、Ｘ^-およびＹ⁺は前記式（２）と同様である）

(In the formula, R ¹ is the same as in the above formula (3), and X ⁻ and Y ⁺ are the same as in the above formula (2)).

（式中、Ｒ¹は前記式（５）と同様であり、Ｘ^-およびＹ⁺は前記式（２）と同様である）

(In the formula, R ¹ is the same as in the above formula (5), and X ⁻ and Y ⁺ are the same as in the above formula (2)).

In the formulas (2), (4) and (6), X ⁻ represents an m-valent inorganic anion or organic anion, and is preferably a medically acceptable anion. m is an integer of 1-4. For example, when m is 2, one X ⁻ ion and two molecules of carnitine cation moiety form a pair. The same applies when m is 3 or 4. Specific examples thereof include, for example, inorganic ions such as hydroxide ions, nitrate ions, sulfate ions, carbonate ions, hydrogencarbonate ions and halides; formate ions, acetate ions, citrate ions, tartrate ions, oxalate ions, Organic ions such as a fumarate ion, an anion of a saturated or unsaturated fatty acid having 3 to 20 carbon atoms which may have a branch, an anion of carnitine and its derivative, an anion of ascorbic acid, an anion of ascorbyl phosphate and its derivative ; Among these, hydroxide ions, halide ions, citrate ions, halogenated citrate ions, carnitine and anions of derivatives thereof are preferable from the viewpoint of compounding properties as an external preparation for skin, particularly cosmetics, and halides. Ions are most preferred.

In formulas (2), (4) and (6), Y ⁺ represents an n-valent cation or organic cation, and n is an integer of 1 to 4. For example, when n is 2, one Y ⁺ ion and two molecules of carnitine anion moiety form a pair. The same applies when n is 3 or 4. Y ⁺ is preferably a medically acceptable cation, and specific examples thereof include, for example, hydrogen ion, sodium ion, potassium ion, calcium ion, magnesium ion, zinc ion, ammonium ion, carnitine and derivatives thereof. And cations. Among these, hydrogen ions, sodium ions, potassium ions, carnitine and cations of derivatives thereof are preferable, and hydrogen ions are most preferable from the viewpoint of compounding properties as an external preparation for skin, particularly cosmetics.

As the elastin production promoter of the present invention, carnitine and its derivative salt specified by the combination with X ⁻ , Y ⁺ , R ¹ and R ² may be used singly or in combination of two or more. May be used. In the preparation containing a carnitine salt, X ⁻ and Y ⁺ may each be a single ion or a mixture of a plurality of ions. The valences of X ⁻ and Y ⁺ do not necessarily match.

  In the elastin production promoter of the present invention, the content of at least one selected from carnitine and a salt thereof and a derivative of carnitine and a salt thereof is usually 0.2 to 500 mM in the total amount of the elastin production promoter, preferably It is 1.0-250 mM, More preferably, it is 2.0-100 mM, More preferably, it is 10-50 mM. The content is the amount of carnitine or a derivative thereof when carnitine or a derivative thereof is used alone, and the carnitine salt or a carnitine derivative when a carnitine salt or a carnitine derivative salt is used alone. In the case where these salts are used in combination, this means the total amount of these components used in combination.

  In such an amount, when elastin production promoter contains at least one selected from carnitine and salts thereof and carnitine derivatives and salts thereof, elastin production can be effectively promoted. When an elastin production promoter is used in, for example, a skin external preparation such as a cosmetic, it is preferable because the efficacy effect required for the skin external preparation can be sufficiently exhibited.

  The elastin production promoter of the present invention may contain components generally used for elastin production promoters as long as the elastin production promotion effect is not impaired in addition to the above carnitine and salts thereof and carnitine derivatives and salts thereof. Good. Alternatively, a carnitine derivative and a salt thereof may be dispersed in a solvent such as water or alcohol. When the elastin production promoter of the present invention is used in a skin external preparation such as cosmetics, components generally used in skin external preparations such as cosmetics may be blended within a range that does not impair the effects of the present invention.

<Prescription example>
Cosmetics and the like can be prepared using the elastin production promoter of the present invention. For example, a cosmetic can be prepared based on the components shown in Table 1. (The values in the table are% by mass with the total amount being 100%)

  For example, each composition of A, B, and C shown in Table 1 is heated to 85 ° C. and uniformly mixed to prepare compositions A to C, and then the composition A is applied to a homomixer while the composition A is applied to a homomixer. Are gradually added in this order to composition B (elastin production promoter) and composition C. Next, stirring is continued while cooling to about 30 ° C. with ice, and then allowed to cool to room temperature, whereby cosmetics 1 to 5 can be obtained.

表中、単位はｗｔ％である。

In the table, the unit is wt%.

  In addition, cosmetics can also be prepared by the methods described in Examples of JP-A-2007-119441.

[Example 1]
By the following test, the effect of hexyldecanoic acid-L-carnitine as an elastin production promoter was confirmed using fibroblasts.

Seeding human normal fibroblasts (NB1RGB) in a Glc-containing DMEM medium (10 wt% FBS, 1 wt% PS solution) injected into each well of a 24 well plate so as to be 1.5 × 10 ⁴ cells / cm ² The cells were cultured in an incubator at 37 ° C. (5 vol% CO ₂ ) for 3 days. After completion of the culture, the medium was removed with an aspirator, and the obtained cells were mixed with a fatty acid-added medium (5% FBS, 10% albumin, hexyldecanoic acid L-carnitine (HLC) (hereinafter also referred to as a test sample) at a concentration of 10 μM. 100 mM of 4 mM sodium palmitate) was added, and cultured for 2 days in the same manner as described above. After completion of the culture, the medium was removed with an aspirator, and 100 uL of a fatty acid-added medium (5% FBS, 10% albumin, 4 mM sodium palmitate) was added to the obtained cells, and the cells were cultured in the same manner as described above for 2 days. After completion of the culture, the medium was removed with an aspirator, and the amount of intracellular elastin A was measured on the collected cells using FASTIN ELASTIN Assay Kit (manufactured by Biocolor) by the following method.

  The cells collected after removing the medium (hereinafter referred to as measurement cells) were washed twice with 500 μL of phosphate buffered saline (PBS solution), and 150 μL of cell detachment solution (C1419, SIGMA) was added. In addition, cells were collected. 50 μL of a 1.00 M oxalic acid aqueous solution was added to the recovered cell-containing solution (oxalic acid concentration after mixing: 0.25 M) and heated at 100 ° C. for 1 hour to obtain an elastin-solubilized solution.

  100 μL of the above elastin-solubilized solution cooled to room temperature was placed in a 1.5 mL tube, 100 μL of Precipitation Reagent that had been cooled to 4 ° C. was added, stirred with a vortex mixer, and allowed to stand for 15 minutes. This was centrifuged for 10 minutes at a centrifugal force of 10,000 g, and then the supernatant was removed. 1 mL of Dye Reagent was added to the tube, and the mixture was stirred with a vortex mixer and then incubated for 90 minutes on a tube shaker. After incubation, it was centrifuged at 10,000 g for 10 minutes. After centrifugation, the supernatant was removed, 250 μL of Dye Dessert Reagent was added, and the mixture was stirred with a vortex mixer and allowed to stand for 10 minutes. After standing, the mixture was stirred again, and the solution was transferred to a 96 well plate. The absorbance at 513 nm was measured with a plate reader (Infinite M200, TECAN).

  Instead of the above elastin solubilizing solution, the same operation as described above was performed on the standard elastin solution, the absorbance was measured, and a calibration curve was obtained. From the obtained calibration curve, the amount of elastin in the elastin solubilized solution was calculated, and the amount of elastin A was obtained.

In addition, the cell number relative value B was measured by the Neutral Red method for the above measurement cells by the following method.
100 μL of Neutral 150 μg / mL PBS solution (0.5% FBS) was added to the measurement cells, incubated for 1 hour in a 37 ° C. incubator (5% CO ₂ ), the solution was removed, and 4 wt% 200 uL of paraformaldehyde phosphate buffer was added and allowed to stand for 1 minute. After standing, the solution was removed, and 100 μL of a solution obtained by mixing 1 wt% of acetic acid with 50% ethanol aqueous solution was added and incubated at room temperature for 20 minutes. After incubation, the absorbance at 540 nm was measured with the plate reader. This absorbance was defined as the cell number relative value B.

  Also, instead of the fatty acid-added medium containing the test sample, the same operation as described above was performed using the fatty acid-added medium not containing the test sample, and the amount of elastin A and the relative number B of cells were measured in the same manner as described above.

  From the obtained results, the elastin production rate (%) per cell was calculated by the following formula (1). Table 2 shows the calculation results.

但し、式（１）中、エラスチン値α、エラスチン値βおよびエラスチン値は以下のとおりである。
エラスチン値α: 被験試料を用いた場合に得られたエラスチン値
エラスチン値β: 被験試料を用いなかった場合（コントロール）に得られたエラスチン値
エラスチン値 : エラスチン量Ａ／細胞相対値Ｂ

However, in the formula (1), the elastin value α, the elastin value β, and the elastin value are as follows.
Elastin value α: Elastin value obtained when test sample was used Elastin value β: Elastin value obtained when test sample was not used (control) Elastin value: Elastin amount A / cell relative value B

[Example 2]
The elastin production rate was measured in the same manner as in Example 1 except that the concentration of hexyldecanoic acid L-carnitine in the fatty acid-added medium containing hexyldecanoic acid L-carnitine was changed to 100 μM. The results are shown in Table 2.

[Comparative Example 1]
The elastin production rate was measured in the same manner as in Example 1 except that the fatty acid-added medium containing hexyldecanoic acid L-carnitine was changed to a fatty acid-added medium not containing hexyldecanoic acid L-carnitine. The results are shown in Table 2.

ＨＬＣ：ヘキシルデカン酸L-カルニチン （昭和電工株式会社製）

HLC: Hexyldecanoic acid L-carnitine (manufactured by Showa Denko KK)

Claims (9)

  An elastin production promoter comprising at least one selected from carnitine and salts thereof and carnitine derivatives and salts as an active ingredient. The elastin production according to claim 1, wherein the carnitine and a salt thereof and a carnitine derivative and a salt thereof are a compound represented by the following general formula (1) and a compound represented by the general formula (2). Accelerator.

(In the formula, R ⁰ represents any of an aliphatic hydrocarbon group having 1 to 37 carbon atoms, a hydrogen atom, and —COR ^1. R ¹ represents an aliphatic hydrocarbon group having 1 to 36 carbon atoms)

(In the formula, R ⁰ is the same as in the above formula (1), X ⁻ represents an m-valent inorganic anion or organic anion, and Y ⁺ represents an n-valent inorganic cation or organic cation. Independently represents an integer of 1 to 4) The compound represented by the general formula (1) is a compound represented by the following general formula (3), and the compound represented by the general formula (2) is a compound represented by the following general formula (4). 2. The elastin production promoter according to 2.

(Wherein R ¹ represents an aliphatic hydrocarbon group having 1 to 36 carbon atoms)

(In the formula, R ¹ is the same as in the above formula (3), and X ⁻ and Y ⁺ are the same as in the general formula (2)). The compound represented by the general formula (3) is a compound represented by the following general formula (5), and the compound represented by the general formula (4) is a compound represented by the following general formula (6). 3. The elastin production promoter according to 3.

(In the formula, R ² and R ³ each independently represents an aliphatic hydrocarbon group having 1 to 18 carbon atoms)

(Wherein R ² and R ³ are the same as in general formula (5), and X ⁻ and Y ⁺ are the same as in general formula (2)). The elastin production promotion according to claim 4, wherein R ² and R ^{3 in} formula (5) and formula (6) are each independently an aliphatic hydrocarbon group having ³ to 16 carbon atoms. Agent. In each of the formulas (5) and (6), one of R ² and R ³ are n- hexyl group, according to claim 4, wherein the other is a n- octyl group Elastin production promoter. X ⁻ in the formulas (2), (4) and (6) is a hydroxide ion, nitrate ion, sulfate ion, carbonate ion, hydrogen carbonate ion, halide ion, formate ion, acetate ion, citrate ion. An anion selected from the group consisting of a tartrate ion, an oxalate ion, a fumarate ion, an anion of a fatty acid having 3 to 20 carbon atoms, an anion of carnitine and its derivative, an anion of ascorbic acid, an anion of ascorbyl phosphate and its derivative The elastin production promoter according to claim 2, wherein the elastin production promoter is present. Y ⁺ in the formulas (2), (4) and (6) is selected from the group consisting of cations of hydrogen ion, sodium ion, potassium ion, calcium ion, magnesium ion, zinc ion, ammonium ion, carnitine and derivatives thereof. The elastin production promoter according to any one of claims 2 to 7, wherein the elastin production promoter is selected.   The elastin production according to any one of claims 1 to 8, wherein the content of at least one selected from carnitine and a salt thereof and a carnitine derivative and a salt thereof is 0.2 to 500 mM. Accelerator.